In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Millennium acquires Cor Therapeutics for $1.8bn

Executive Summary

Millennium Pharmaceuticals (personalized medicine) will acquire Cor Therapeutics (cardiovascular diseases) in a $1.8bn stock swap. For each Cor share, stockholders will receive 0.9873 Millennium common shares (valued at $32.40 each, a 53% premium to Cor's market average).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Stock
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register